Molecular structure of O-1602, CAS Number: 317321-41-8
O-1602 (CAS 317321-41-8)
Alternate Names:
5-methyl-4-[(1R, 6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol
Application:
O-1602 is a cannabidiol analog and activator of the GRP55 receptor
CAS Number:
317321-41-8
Molecular Weight:
258.4
Molecular Formula:
C17H22O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
O-1602 is an analog of cannabidiol and an activator of the novel endocannabinoid receptor GRP55. O-1602 is described to produce vasodilation which is not mediated by interaction with GRP55 or the CB1/CB2 receptors.
O-1602 (CAS 317321-41-8) References
- Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. | Járai, Z., et al. 1999. Proc Natl Acad Sci U S A. 96: 14136-41. PMID: 10570211
- The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. | Johns, DG., et al. 2007. Br J Pharmacol. 152: 825-31. PMID: 17704827
- The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. | Schuelert, N. and McDougall, JJ. 2011. Neurosci Lett. 500: 72-6. PMID: 21683763
- The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. | Schicho, R., et al. 2011. Inflamm Bowel Dis. 17: 1651-64. PMID: 21744421
- The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. | Díaz-Arteaga, A., et al. 2012. Diabetes Obes Metab. 14: 234-43. PMID: 21981246
- The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. | Breen, C., et al. 2012. Neurosci Lett. 508: 119-22. PMID: 22227298
- The atypical cannabinoid O-1602: targets, actions, and the central nervous system. | Ashton, JC. 2012. Cent Nerv Syst Agents Med Chem. 12: 233-9. PMID: 22831390
- Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. | Li, K., et al. 2013. Pancreas. 42: 123-9. PMID: 22850623
- A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. | Li, K., et al. 2013. Neuropharmacology. 71: 255-63. PMID: 23603203
- Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity. | Simcocks, AC., et al. 2019. Endocr Connect. 8: 203-216. PMID: 30707678
- Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer. | Tomko, A., et al. 2019. Front Pharmacol. 10: 1124. PMID: 31611800
- O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment. | Wróbel, A., et al. 2020. Front Pharmacol. 11: 1002. PMID: 32733244
- O-1602 Promotes Hepatic Steatosis through GPR55 and PI3 Kinase/Akt/SREBP-1c Signaling in Mice. | Kang, S., et al. 2021. Int J Mol Sci. 22: PMID: 33803038
Inhibitor of:
PLC β2.Activator of:
CNR1, GPR18, GPR55, and NAB2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
O-1602, 1 mg | sc-202745 | 1 mg | $208.00 | |||
O-1602, 5 mg | sc-202745A | 5 mg | $416.00 |